Year All News202420232022202120202019201820172016 Nov 28 2019 Achilles Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference Read More + Nov 14 2019 Achilles Therapeutics to Present at the Jefferies 2019 London Healthcare Conference Read More + Oct 21 2019 Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer — Brings 20+ years of business development experience — Formerly VP, Business Development for the Immuno-inflammation Therapy Area at GSK Read More + Sep 3 2019 ACHILLES THERAPEUTICS RAISES £100 MILLION IN OVERSUBSCRIBED SERIES B FINANCING Read More + Feb 13 2019 ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN METASTIC OR RECURRENT MELANOMA — Second CTA approval in 2019 — the first was for a NSCLC study Read More + Jan 21 2019 ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER — Ground-breaking clinical trial in patients with significant unmet medical need to start this year Read More +
Nov 28 2019 Achilles Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference Read More +
Nov 14 2019 Achilles Therapeutics to Present at the Jefferies 2019 London Healthcare Conference Read More +
Oct 21 2019 Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer — Brings 20+ years of business development experience — Formerly VP, Business Development for the Immuno-inflammation Therapy Area at GSK Read More +
Sep 3 2019 ACHILLES THERAPEUTICS RAISES £100 MILLION IN OVERSUBSCRIBED SERIES B FINANCING Read More +
Feb 13 2019 ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN METASTIC OR RECURRENT MELANOMA — Second CTA approval in 2019 — the first was for a NSCLC study Read More +
Jan 21 2019 ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER — Ground-breaking clinical trial in patients with significant unmet medical need to start this year Read More +
